Nanoscribe’s microfabrication systems with the underlying Two-Photon Polymerization (2PP) technology enable extremely precise additive manufacturing of nano-, micro- and mesosized structures and objects. More than 2,500 system users benefit from rapid prototyping and manufacturing processes in research laboratories, multi-user facilities and production sites in academia and industry.
The world bioconvergence company CELLINK and Nanoscribe entered into an agreement for Nanoscribe to be part of the CELLINK
Nanoscribe, the pioneer and market leader in high-precision additive manufacturing, strengthens its strategic position by entering the CELLINK. CELLINK was founded in 2016 for commercializing the world’s first universal bioink. The publicly listed company has consistently expanded its portfolio into a bioconvergence company offering solutions for bioprinting, multiomics, cell line development and diagnostics. Nanoscribe will continue developing high-precision additive manufacturing solutions as part of the CELLINK’s business area Bioprinting.
The life science industry is currently going through a very exciting transformation where many processes and technologies are being miniaturized to increase throughput and reduce cost, where price of reagents is a major bottle neck for sequencing. One example is the sample preparation steps for single cell genomics applications. With Nanoscribe’s microfabrication technologies, the CELLINK stays competitive in this transformation and aims to miniaturize devices for a wide range of applications, resulting in internal capabilities to further expand its consumables offering across all business areas.
Nanoscribe’s high-precision 3D printing capabilities for life sciences and medicine
With Nanoscribe, the CELLINK is the world’s first life science company with internal Two-Photon Polymerization (2PP) additive manufacturing capabilities. Nanoscribe’s 2PP technology enables bioprinting of vascular microenvironments at sub-cellular scale, suitable for cell studies and lab-on-a-chip applications, which is expected to contribute to the product development, yielding additional recurring revenue through fabrication of implants, microneedles, microporous membranes, and consumables for omics applications. There are several strong synergies by combining CELLINK’s cutting-edge macro structural bioprinting technology with Nanoscribe’s micro structural bioprinting technology for more realistic tissue architecture, including vascularization, cell supports. The 2PP technology will enable a cross-functional adoption within all three business areas and enhance consumables product development and offerings of the CELLINK. “With Nanoscribe’s state of the art 2PP technology, we will complement our product portfolio and offer a wider range of products to our amazing customers. We are combining our strong, purpose driven growth agenda with trailblazing bioconverging technologies for the sake of improving health all around the world”, emphasizes Erik Gatenholm, CEO of CELLINK.
Versatile microfabrication solutions for cutting-edge research and industrial solutions
As pioneer and a market leader in 2PP-based microfabrication technologies, Nanoscribe looks on a customer base in over 30 countries worldwide in a wide range of different sectors. “We take pride in our state-of-the-art 2PP technology, offering our customers the tools to materialize their ground-breaking ideas. We are a vibrant, award-winning company that continuously strives to maintain our market position, which has been achieved through close relationships with our customers”, says Martin Hermatschweiler, co-founder and CEO of Nanoscribe. Based on the expertise in 2PP-based microfabrication technologies, Nanoscribe continues to empower cutting-edge science and drives industrial innovations in a wide variety of sectors such as bioprinting, microfluidics, microoptics, micromechanics, biomedical engineering, and integrated photonics technologies. “We very much look forward to join the CELLINK and together explore the enormous opportunities with the 2PP technology”, Martin Hermatschweiler continues.